Hölscher, Christian

Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology

Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 986

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 698

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience

Alzheimer's disease research and treatmentsBarrier Structure and Function Studies

Cited by 504

Stimulation on the Positive Phase of Hippocampal Theta Rhythm Induces Long-Term Potentiation That Can Be Depotentiated by Stimulation on the Negative Phase in Area CA1 In Vivo

Hölscher, C., Anwyl, R., & Rowan, M. J. (1997) · The Journal of Neuroscience

Neuroscience and Neuropharmacology ResearchMemory and Neural Mechanisms

Cited by 411

Common pathological processes in Alzheimer disease and type 2 diabetes: A review

Li, L., & Hölscher, C. (2007) · Brain Research Reviews

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 367

The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review

Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 248

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C. (2015) · Neuroscience

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 246

Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system

Hamilton, A., & Hölscher, C. (2009) · NeuroReport

Neuroscience and Neuropharmacology ResearchNeuropeptides and Animal Physiology

Cited by 227

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease

McClean, P. L., Gault, V. A., Harriott, P., & Hölscher, C. (2010) · European Journal of Pharmacology

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 193

Brain insulin resistance: role in neurodegenerative disease and potential for targeting

Hölscher, C. (2020) · Expert Opinion on Investigational Drugs

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 180

Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson’s Disease

Zhang, L., Zhang, L., Li, L., & Hölscher, C. (2019) · Journal of Parkinson's Disease

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 173

Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease

McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 170

GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

Gao, C., Hölscher, C., Liu, Y., & Li, L. (2012) · revneuro

Alzheimer's disease research and treatmentsWnt/β-catenin signaling in development and cancer

Cited by 164

Neuroprotective and anti‐apoptotic effects of liraglutide on SH‐SY 5Y cells exposed to methylglyoxal stress

Sharma, M. K., Jalewa, J., & Hölscher, C. (2014) · Journal of Neurochemistry

Alzheimer's disease research and treatmentsNeuroprotection in Cerebral Ischemia

Cited by 151

Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway

Wang, Z.-J., Li, X.-R., Chai, S.-F., Li, W.-R., Li, S., Hou, M., Li, J.-L., Ye, Y.-C., Cai, H.-Y., Hölscher, C., et al. (2023) · Neuropharmacology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 125

The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain

Parthsarathy, V., & Hölscher, C. (2013) · European Journal of Pharmacology

Neuroinflammation and Neurodegeneration MechanismsEffects of Radiation Exposure

Cited by 119

The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke

Yang, X., Feng, P., Zhang, X., Li, D., Wang, R., Ji, C., Li, G., & Hölscher, C. (2019) · Neuropharmacology

Acute Ischemic Stroke ManagementNeuroprotection in Cerebral Ischemia

Cited by 103

Val8-glucagon-like peptide-1 protects against Aβ1–40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats

Wang, X. H., Li, L., Hölscher, C., Pan, Y. F., Chen, X. R., & Qi, J. S. (2010) · Neuroscience

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 99

The Role of GLP-1 in Neuronal Activity and Neurodegeneration

Hölscher, C. (2010) · Vitamins & Hormones

Alzheimer's disease research and treatmentsDiabetes Treatment and Management

Cited by 74

Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease

Salles, G. N., Calió, M. L., Hölscher, C., Pacheco-Soares, C., Porcionatto, M., & Lobo, A. O. (2020) · Neuropharmacology

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 71

Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research

Yang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology

Neuroprotection in Cerebral IschemiaAcute Ischemic Stroke Management

Cited by 58

Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease

Reich, N., & Hölscher, C. (2020) · Frontiers in Neuroscience

Alzheimer's disease research and treatmentsParkinson's Disease Mechanisms and Treatments

Cited by 48

Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model

Li, L., Zhang, L.-Y., Jin, Q.-Q., & Hölscher, C. (2021) · Neural Regeneration Research

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 38